Methadone in end-of-life pain management


  • Diane L. Chau, MD
  • M. Nathan Mason, MD






Author Biographies

Diane L. Chau, MD

Assistant Professor, Department of Internal Medicine, University of Nevada School of Medicine, Veterans Affairs, Sierra Healthcare Systems, TCU Palliative Care Director, Reno, Nevada.

M. Nathan Mason, MD

Resident, Department of Psychiatry, University of Nevada School of Medicine, Reno, Nevada.


Green CR: Clinical decision making in pain management: Contributions of physician and patient characteristics to variations in practice. J Pain. 2003; 4(1): 29-39.

Glasziou PP: Analgesia and public health: What are the challenges? Am J Ther. 2002; 9(3): 207-213.

Green CR: Physician variability in the management of acute postoperative and cancer pain: A quantitative analysis of the Michigan experience. Pain Med. 2003; 4(1): 8-20.

Della SC: Whole-patient assessment, goal planning, and inflection points: Their role in achieving quality end-of-life care. Clin Geriatr Med. 2004; 20(4): 595-620.

Davis MP: Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Med. 2004; 21(2): 137-142.

Joseph R: Medico-legal case report and commentary: Inadequate pain management in the context of terminal cancer. The case of Lester Tomlinson. Pain Med. 2004; 5(2): 214-229.

Amato L: An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005; 28(4): 321-329.

Drug Topics Red Book. Montvale, NJ: Medical Economics, 2004.

Fishman SM, Wilsey B, Mahajan G, et al: Methadone reincarnated: Novel clinical applications with related concerns. Pain Med. 2002; 3(4); 339-348.

Ripamonti C: Strategies for the treatment of cancer pain in the new millennium. Drugs. 2001; 61(7): 955-977.

Mao J, Price DD, Mayer J: Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain. 1995; 62: 259-274.

Altier N: Management of chronic neuropathic pain with methadone: A review of 13 cases. Clin J Pain. 2005; 21(4): 364-369.

Gagnon B: Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage. 1999; 18(2): 120-125.

Nicholson AB: Methadone for cancer pain. Available online at Retrieved September 14, 2005.

Galer BS, Coyle N, Pasternak GW, et al.: Individual variability in the response to different opioids: Report of five cases. Pain. 1992; 49(1): 87-91.

Wang JS, DeVane CL: Involvement OF CYP3A4, CYP2C8, AND CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003; 31(6): 742-747.

Ripamonti C, Bianchi M: The use of methadone for cancer pain. Hematol Oncol Clin North Am. 2002; 16(3): 543-555.

Cherny NI, Portenoy RK: The management of cancer pain. CA Cancer J Clin. 1994; 44(5): 262-303.

Gourlay GK, Cherry DA, Cousins MJ: A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain. 1986; 25: 297-312.

Fitzgibbon DR, Ready LB: Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to highdose morphine. Pain. 1997; 73: 259-261.

Manfredi PL, Borsook D, Chandler SW, et al: Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations. Pain. 1997; 70: 99-101.

Weinberg DS, Inturrisi CE, Redenberg B, et al: Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther. 1998; 44: 335-342.

Ripamonti C, Zecca E, Brunelli C, et al.: Rectal methadone in cancer patients with pain: A preliminary clinical and pharmacokinetic study. Ann Oncol. 1995; 6: 841-843.

Bruera E, Faisinger R, Moore M, et al: Local toxicity with subcutaneous methadone: Experience of two centers. Pain. 1991; 45: 141-143.

Mathew P, Storey P: Subcutaneous methadone in terminally ill pa tients: manageable local toxicity. J Pain Symptom Manage. 1999; 18: 49-52.

Santiago-Palma J, Khojainova N, Kornick C, et al: Intravenous methadone in the management of chronic cancer pain: Safe and effective starting doses when substituting methadone for fentanyl. Cancer. 2001; 92(7): 1919-1925.

Bruera E, Palmer JL, Bosnjak S, et al.: Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized double-blind study. J Clin Oncol. 2004; 22(1): 185-192.

Bruera E, Sweeney C: Methadone use in cancer patients with Pain: A review. J Palliat Med. 2002; 5(1): 127-138.

Ripamonti C, Bianchi M: The use of methadone for cancer pain. Hematol Oncol Clin North Am. 2002; 16(3): 543-555.

Mercadante S, Casuccio A, Fulfaro F, et al: Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol. 2001; 19(11): 2898-2904.

Mercadante S, Casuccio A, Calderone L: Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 1999; 17(10): 3307-3312.

Morley JS, Makin MK: The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev. 1998; 5: 51-58.

Maremmani I, Pacini M, Cesaroni C, et al.: QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res. 2005; 11: 44-49.

Ower K, Morley-Forster P, Moulin D: Fluctuating QTc interval in an asymptomatic patient treated with methadone for chronic pain. J Opioid Mgmt. 2005; 1(2): 73-76.

Kornick CA, Kilborn MJ, Santiago-Palma J, et al.: QTc prolongation with intravenous methadone. Pain. 2003; 105(3): 499-506.

Daniell HW: Hypogonadism in men consuming sustained action oral opioids. J Pain. 2002; 3(5): 377-384.

Brown R, Balousek S, Mundt M, et al.: Methadone maintenance and male sexual dysfunction. J Addict Dis. 2005; 24(2): 91-106.

Toombs JD, Kral LA: Methadone treatment for pain states. Am Fam Phys. 2005; 71(7): 1353-1358.




How to Cite

Chau, MD, D. L., and M. N. Mason, MD. “Methadone in End-of-Life Pain Management”. Journal of Opioid Management, vol. 1, no. 5, Nov. 2005, pp. 244-8, doi:10.5055/jom.2005.0053.